{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:17:49Z","timestamp":1783639069808,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tuberculosis is the leading cause of death among people living with HIV (PLH). Preventive tuberculosis therapy reduces mortality in PLH, especially in those with a positive tuberculin skin test (TST). New, more specific technologies for detecting latent tuberculosis infection (LTBI) are now commercially available. We sought to analyse the cost-effectiveness of four different strategies for the diagnosis of LTBI in PLH in Brazil, from the Brazilian public health care system perspective. We developed a Markov state-transition model comparing four strategies for the diagnosis of LTBI over 20\u00a0years. The strategies consisted of TST with the currently used protein purified derivative (PPD RT 23), two novel skin tests using recombinant allergens (Diaskintest [Generium Pharmaceutical, Moscow, Russia] and EC [Zhifei Longcom Biologic Pharmacy Co., Anhui, China]), and the QuantiFERON-TB-Gold-Plus (Qiagen, Hilden, Germany). The main outcome was cost (in 2020 US dollars) per quality-adjusted life years (QALY). For the base case scenario, the Diaskintest was dominant over all other examined strategies. The cost saving estimate per QALY was US $1375. In sensitivity analyses, the Diaskintest and other newer tests remained cost-saving compared to TST. For PLH, TST could be replaced by more specific tests in Brazil, considering the current national recommendations.<\/jats:p>","DOI":"10.1038\/s41598-020-78737-w","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T11:20:56Z","timestamp":1607685656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV"],"prefix":"10.1038","volume":"10","author":[{"given":"Ricardo E.","family":"Steffen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afranio","family":"Kritski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anete","family":"Trajman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"78737_CR1","volume-title":"Global Tuberculosis Report 2020","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Global Tuberculosis Report 2020 (World Health Organization, Geneva, 2020)."},{"key":"78737_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","volume":"34","author":"C Dye","year":"2013","unstructured":"Dye, C., Glaziou, P., Floyd, K. & Raviglione, M. Prospects for tuberculosis elimination. Annu. Rev. Public Health 34, 271\u2013286. https:\/\/doi.org\/10.1146\/annurev-publhealth-031912-114431 (2013).","journal-title":"Annu. Rev. Public Health"},{"key":"78737_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171.pub3","author":"C Akolo","year":"2010","unstructured":"Akolo, C., Adetifa, I., Shepperd, S. & Volmink, J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD000171.pub3 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"key":"78737_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"The TEMPRANO ANRS 12136 Study Group","year":"2015","unstructured":"The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med. 373, 808\u2013822. https:\/\/doi.org\/10.1056\/NEJMoa1507198 (2015).","journal-title":"N. Engl. J. Med."},{"key":"78737_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1076-0","author":"RK Gupta","year":"2020","unstructured":"Gupta, R. K. et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-1076-0 (2020).","journal-title":"Nat. Med."},{"key":"78737_CR6","unstructured":"United Nations General Assembly. Resolution adopted by the General Assembly on 10 October 2018: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. A\/RES\/73\/3. Available from: https:\/\/www.who.int\/publications\/m\/item\/political-declaration-of-the-un-general-assembly-high-level-meeting-on-the-fight-against-tuberculosis (2018). Accessed 4 December 2020."},{"key":"78737_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf, H., Hill, P. C., Matteelli, A., Getahun, H. & Menzies, D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: A systematic review and meta-analysis. Lancet Infect. Dis. 16, 1269\u20131278. https:\/\/doi.org\/10.1016\/S1473-3099(16)30216-X (2016).","journal-title":"Lancet Infect. Dis."},{"key":"78737_CR8","unstructured":"World Health Organization. Latent TB infection: Updated and consolidated guidelines for programmatic management (World Health Organization, Geneva, 2018)."},{"key":"78737_CR9","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Protocolo de vigil\u00e2ncia da infec\u00e7\u00e3o latente pelo Mycobacterium tuberculosis no Brasil. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis (2018)."},{"key":"78737_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/QAD.0000000000000535","volume":"29","author":"T Samandari","year":"2015","unstructured":"Samandari, T. et al. Tuberculosis incidence after 36 months\u2019 isoniazid prophylaxis in HIV-infected adults in Botswana: A posttrial observational analysis. AIDS 29, 351\u2013359. https:\/\/doi.org\/10.1097\/QAD.0000000000000535 (2015).","journal-title":"AIDS"},{"key":"78737_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171","author":"D Wilkinson","year":"2000","unstructured":"Wilkinson, D. Drugs for preventing tuberculosis in HIV infected persons. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD000171 (2000).","journal-title":"Cochrane Database Syst. Rev."},{"key":"78737_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/s0140-6736(14)60162-8","volume":"384","author":"MX Rangaka","year":"2014","unstructured":"Rangaka, M. X. et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial. Lancet 384, 682\u2013690. https:\/\/doi.org\/10.1016\/s0140-6736(14)60162-8 (2014).","journal-title":"Lancet"},{"key":"78737_CR13","doi-asserted-by":"publisher","first-page":"e0142290","DOI":"10.1371\/journal.pone.0142290","volume":"10","author":"HT Ayele","year":"2015","unstructured":"Ayele, H. T., Mourik, M. S., Debray, T. P. & Bonten, M. J. Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: A systematic review and meta-analysis of randomized trials. PLoS ONE 10, e0142290. https:\/\/doi.org\/10.1371\/journal.pone.0142290 (2015).","journal-title":"PLoS ONE"},{"key":"78737_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.15585\/mmwr.mm6824a4","volume":"68","author":"Nationwide Shortage of Tuberculin Skin Test Antigens","year":"2019","unstructured":"Nationwide Shortage of Tuberculin Skin Test Antigens. CDC recommendations for patient care and public health practice. MMWR Morb. Mortal. Wkly. Rep. 68, 552\u2013553. https:\/\/doi.org\/10.15585\/mmwr.mm6824a4 (2019).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"78737_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai, M., Zwerling, A. & Menzies, D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann. Intern. Med. 149, 177\u2013184. https:\/\/doi.org\/10.7326\/0003-4819-149-3-200808050-00241 (2008).","journal-title":"Ann. Intern. Med."},{"key":"78737_CR16","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1590\/1413-812320141912.04642014","volume":"19","author":"R Guimaraes","year":"2014","unstructured":"Guimaraes, R. Technological incorporation in the Unified Health System (SUS): The problem and ensuing challenges. Cien. Saude. Colet. 19, 4899\u20134908. https:\/\/doi.org\/10.1590\/1413-812320141912.04642014 (2014).","journal-title":"Cien. Saude. Colet."},{"key":"78737_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/QAD.0000000000002398","volume":"34","author":"LH Chaisson","year":"2020","unstructured":"Chaisson, L. H. et al. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. AIDS 34, 139\u2013147. https:\/\/doi.org\/10.1097\/QAD.0000000000002398 (2020).","journal-title":"AIDS"},{"key":"78737_CR18","unstructured":"Kiselev, V. I. et al. \u200b[Clinical trials of the new skin test Diaskintest for the diagnosis of tuberculosis]. Probl. Tuberk. Bolezn. Legk. 11\u201316. Russian. (2009)."},{"issue":"889","key":"78737_CR19","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1016\/j.cmi.2016.07.015","volume":"22","author":"F Li","year":"2016","unstructured":"Li, F. et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: An open-label, randomized, two-centre phase 2a clinical trial. Clin. Microbiol. Infect. 22(889), e889\u2013889.e816. https:\/\/doi.org\/10.1016\/j.cmi.2016.07.015 (2016).","journal-title":"Clin. Microbiol. Infect."},{"key":"78737_CR20","first-page":"1192","volume":"10","author":"M Farhat","year":"2006","unstructured":"Farhat, M., Greenaway, C., Pai, M. & Menzies, D. False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria?. Int. J. Tuberc. Lung Dis. 10, 1192\u20131204 (2006).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"78737_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tube.2017.06.002","volume":"106","author":"E Petruccioli","year":"2017","unstructured":"Petruccioli, E. et al. Analytical evaluation of QuantiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinb) 106, 38\u201343. https:\/\/doi.org\/10.1016\/j.tube.2017.06.002 (2017).","journal-title":"Tuberculosis (Edinb)"},{"key":"78737_CR22","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos. Departamento de Ci\u00eancia e Tecnologia. Diretrizes metodol\u00f3gicas : Diretriz de Avalia\u00e7\u00e3o Econ\u00f4mica\/Minist\u00e9rio da Sa\u00fade, Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos, Departamento de Ci\u00eancia e Tecnologia, 2nd edn. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade. (2014)."},{"key":"78737_CR23","first-page":"146","volume":"20","author":"MC La Mantoux","year":"1912","unstructured":"La Mantoux, M. C. voie intradermique en tuberculinoth\u00e9rapie. Presse Med. 20, 146\u2013148 (1912).","journal-title":"Presse Med."},{"key":"78737_CR24","unstructured":"QIAGEN. QuantiFERON\u00ae-TB Gold Plus (QFT\u00ae-Plus) ELISA Package Insert Rev. 01. April 2019.\u00a0 Available from: https:\/\/www.quantiferon.com\/wp-content\/uploads\/2020\/01\/L1083163-R06-QF-TB-Gold-Plus-ELISA-IFU-CE.pdf. Accessed 4  December 2020."},{"key":"78737_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/QAI.0b013e31820b07ab","volume":"56","author":"A Cattamanchi","year":"2011","unstructured":"Cattamanchi, A. et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: A systematic review and meta-analysis. J. Acquir. Immune Defic. Syndr. 56, 230\u2013238. https:\/\/doi.org\/10.1097\/QAI.0b013e31820b07ab (2011).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"78737_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jinf.2019.08.018","volume":"79","author":"G Sotgiu","year":"2019","unstructured":"Sotgiu, G. et al. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: A systematic review and meta-analysis. J. Infect. 79, 444\u2013453. https:\/\/doi.org\/10.1016\/j.jinf.2019.08.018 (2019).","journal-title":"J. Infect."},{"key":"78737_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijid.2019.06.014","volume":"86","author":"IY Nikitina","year":"2019","unstructured":"Nikitina, I. Y. et al. Comparative performance of QuantiFERON-TB Gold versus skin test with tuberculosis recombinant allergen (Diaskintest) among patients with suspected pulmonary tuberculosis in Russia. Int. J. Infect. Dis. 86, 18\u201324. https:\/\/doi.org\/10.1016\/j.ijid.2019.06.014 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"78737_CR28","first-page":"S249","volume":"24","author":"M Krutikov","year":"2020","unstructured":"Krutikov, M. et al. 51st World Conference on Lung Health of the International Union against tuberculosis and lung disease. Int. J. Tuberc. Lung Dis. Virtual. Event. 24, S249-250 (2020).","journal-title":"Int. J. Tuberc. Lung Dis. Virtual. Event."},{"key":"78737_CR29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/j.1524-4733.2008.00355.x","volume":"11","author":"N Guo","year":"2008","unstructured":"Guo, N. et al. Health state utilities in latent and active tuberculosis. Value Health 11, 1154\u20131161. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00355.x (2008).","journal-title":"Value Health"},{"key":"78737_CR30","doi-asserted-by":"publisher","DOI":"10.5539\/gjhs.v3n1p203","author":"MS Awan","year":"2011","unstructured":"Awan, M. S., Waqas, M., Aslam, M. A. & Sarwar, M. Measurement of SF-6D utility among patients with active tuberculosis. Glob. J. Health Sci. https:\/\/doi.org\/10.5539\/gjhs.v3n1p203 (2011).","journal-title":"Glob. J. Health Sci."},{"key":"78737_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5588\/ijtld.12.0123","volume":"17","author":"DW Dowdy","year":"2013","unstructured":"Dowdy, D. W. et al. Quality of life among people treated for tuberculosis and human immunodeficiency virus in Rio de Janeiro, Brazil. Int. J. Tuberc. Lung Dis. 17, 345\u2013347. https:\/\/doi.org\/10.5588\/ijtld.12.0123 (2013).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"78737_CR32","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1097\/00002030-199908200-00016","volume":"13","author":"JC Bell","year":"1999","unstructured":"Bell, J. C., Rose, D. N. & Sacks, H. S. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS 13, 1549\u20131556. https:\/\/doi.org\/10.1097\/00002030-199908200-00016 (1999).","journal-title":"AIDS"},{"key":"78737_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00042560-199709010-00009","volume":"16","author":"DR Holtgrave","year":"1997","unstructured":"Holtgrave, D. R. & Pinkerton, S. D. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16, 54\u201362. https:\/\/doi.org\/10.1097\/00042560-199709010-00009 (1997).","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"78737_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.7326\/0003-4819-129-10-199811150-00005","volume":"129","author":"DN Rose","year":"1998","unstructured":"Rose, D. N. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. Ann. Intern. Med. 129, 779\u2013786. https:\/\/doi.org\/10.7326\/0003-4819-129-10-199811150-00005 (1998).","journal-title":"Ann. Intern. Med."},{"key":"78737_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12879-017-2473-y","volume":"17","author":"RO da Silva Escada","year":"2017","unstructured":"da Silva Escada, R. O. et al. Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil\u2014Associated factors and causes of death. BMC Infect. Dis. 17, 373. https:\/\/doi.org\/10.1186\/s12879-017-2473-y (2017).","journal-title":"BMC Infect. Dis."},{"key":"78737_CR36","doi-asserted-by":"publisher","first-page":"e0225197","DOI":"10.1371\/journal.pone.0225197","volume":"14","author":"RB Loureiro","year":"2019","unstructured":"Loureiro, R. B. et al. Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil. PLoS ONE 14, e0225197. https:\/\/doi.org\/10.1371\/journal.pone.0225197 (2019).","journal-title":"PLoS ONE"},{"key":"78737_CR37","doi-asserted-by":"publisher","first-page":"e59546","DOI":"10.1371\/journal.pone.0059546","volume":"8","author":"RE Steffen","year":"2013","unstructured":"Steffen, R. E. et al. Cost-effectiveness of Quantiferon(R)-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PLoS ONE 8, e59546. https:\/\/doi.org\/10.1371\/journal.pone.0059546 (2013).","journal-title":"PLoS ONE"},{"key":"78737_CR38","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","volume":"22","author":"HC Turner","year":"2019","unstructured":"Turner, H. C., Lauer, J. A., Tran, B. X., Teerawattananon, Y. & Jit, M. Adjusting for inflation and currency changes within health economic studies. Value Health 22, 1026\u20131032. https:\/\/doi.org\/10.1016\/j.jval.2019.03.021 (2019).","journal-title":"Value Health"},{"key":"78737_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods, B., Revill, P., Sculpher, M. & Claxton, K. Country-level cost-effectiveness thresholds: Initial estimates and the need for further research. Value Health 19, 929\u2013935. https:\/\/doi.org\/10.1016\/j.jval.2016.02.017 (2016).","journal-title":"Value Health"},{"key":"78737_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/11586190-000000000-00000","volume":"14","author":"A Kowada","year":"2010","unstructured":"Kowada, A. Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy. Mol. Diagn. Ther. 14, 367\u2013373. https:\/\/doi.org\/10.2165\/11586190-000000000-00000 (2010).","journal-title":"Mol. Diagn. Ther."},{"issue":"Suppl 3","key":"78737_CR41","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1086\/314075","volume":"31","author":"D Menzies","year":"2000","unstructured":"Menzies, D. What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us?. Clin. Infect. Dis. 31(Suppl 3), S71-74. https:\/\/doi.org\/10.1086\/314075 (2000).","journal-title":"Clin. Infect. Dis."},{"key":"78737_CR42","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1001\/jamainternmed.2017.3941","volume":"177","author":"A Tasillo","year":"2017","unstructured":"Tasillo, A. et al. Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model. JAMA Intern. Med. 177, 1755\u20131764. https:\/\/doi.org\/10.1001\/jamainternmed.2017.3941 (2017).","journal-title":"JAMA Intern. Med."},{"key":"78737_CR43","doi-asserted-by":"publisher","first-page":"m549","DOI":"10.1136\/bmj.m549","volume":"368","author":"JR Campbell","year":"2020","unstructured":"Campbell, J. R., Winters, N. & Menzies, D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: Systematic review and meta-analysis. BMJ 368, m549. https:\/\/doi.org\/10.1136\/bmj.m549 (2020).","journal-title":"BMJ"},{"key":"78737_CR44","unstructured":"Brasil. Presid\u00eancia da Rep\u00fablica. Decreto no 7.646, de 21 de dezembro de 2011. Disp\u00f5e sobre a Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade e sobre o processo administrativo para incorpora\u00e7\u00e3o, exclus\u00e3o e altera\u00e7\u00e3o de tecnologias em sa\u00fade pelo Sistema \u00danico de Sa\u00fade. Di\u00e1rio Oficial da Uni\u00e3o. Se\u00e7\u00e3o 1. 22\/12\/2011. p. 3. Available from:\u00a0http:\/\/www.planalto.gov.br\/CCIVIL_03\/_Ato2011-2014\/2011\/Decreto\/D7646.htm (2011). Accessed on 11 November 2020."},{"key":"78737_CR45","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1183\/13993003.01910-2015","volume":"47","author":"M Pai","year":"2016","unstructured":"Pai, M. & Sotgiu, G. Diagnostics for latent TB infection: Incremental, not transformative progress. Eur. Respir. J. 47, 704\u2013706. https:\/\/doi.org\/10.1183\/13993003.01910-2015 (2016).","journal-title":"Eur. Respir. J."},{"key":"78737_CR46","first-page":"962","volume":"13","author":"JL Burgos","year":"2009","unstructured":"Burgos, J. L. et al. Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico. Int. J. Tuberc. Lung Dis. 13, 962\u2013968 (2009).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"78737_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40258-015-0183-4","volume":"13","author":"JR Campbell","year":"2015","unstructured":"Campbell, J. R., Sasitharan, T. & Marra, F. A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection. Appl. Health Econ. Health Policy 13, 325\u2013340. https:\/\/doi.org\/10.1007\/s40258-015-0183-4 (2015).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"78737_CR48","first-page":"747","volume":"11","author":"RK Shrestha","year":"2007","unstructured":"Shrestha, R. K. et al. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int. J. Tuberc. Lung Dis. 11, 747\u2013754 (2007).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"78737_CR49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12879-017-2810-1","volume":"17","author":"ML Bastos","year":"2017","unstructured":"Bastos, M. L. et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: A retrospective cohort analysis. BMC Infect. Dis. 17, 718. https:\/\/doi.org\/10.1186\/s12879-017-2810-1 (2017).","journal-title":"BMC Infect. Dis."},{"key":"78737_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00021-18","author":"PK Drain","year":"2018","unstructured":"Drain, P. K. et al. Incipient and subclinical tuberculosis: A clinical review of early stages and progression of infection. Clin. Microbiol. Rev. https:\/\/doi.org\/10.1128\/CMR.00021-18 (2018).","journal-title":"Clin. Microbiol. Rev."},{"key":"78737_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/archinternmed.2008.524","volume":"169","author":"MA de Perio","year":"2009","unstructured":"de Perio, M. A., Tsevat, J., Roselle, G. A., Kralovic, S. M. & Eckman, M. H. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch. Intern. Med. 169, 179\u2013187. https:\/\/doi.org\/10.1001\/archinternmed.2008.524 (2009).","journal-title":"Arch. Intern. Med."},{"key":"78737_CR52","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.5588\/ijtld.14.0108","volume":"18","author":"M Azadi","year":"2014","unstructured":"Azadi, M. et al. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB\/HIV in Rio (THRio) Study. Int. J. Tuberc. Lung Dis. 18, 1443\u20131448. https:\/\/doi.org\/10.5588\/ijtld.14.0108 (2014).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"78737_CR53","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/cid\/ciu849","volume":"60","author":"JE Golub","year":"2015","unstructured":"Golub, J. E. et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB\/HIV in Rio (THRio) study. Clin. Infect. Dis. 60, 639\u2013645. https:\/\/doi.org\/10.1093\/cid\/ciu849 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"78737_CR54","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies, D. et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N. Engl. J. Med. 379, 440\u2013453. https:\/\/doi.org\/10.1056\/NEJMoa1714283 (2018).","journal-title":"N. Engl. J. Med."},{"key":"78737_CR55","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02048-2019","author":"LA Ronald","year":"2020","unstructured":"Ronald, L. A. et al. Treatment with isoniazid or rifampin for latent tuberculosis infection: Population-based study of hepatotoxicity, completion and costs. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.02048-2019 (2020).","journal-title":"Eur. Respir. J."},{"key":"78737_CR56","first-page":"847","volume":"3","author":"GW Comstock","year":"1999","unstructured":"Comstock, G. W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int. J. Tuberc. Lung Dis. 3, 847\u2013850 (1999).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"78737_CR57","first-page":"555","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","unstructured":"International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull. World Health Organ. 60, 555\u2013564 (1982).","journal-title":"Bull. World Health Organ."},{"key":"78737_CR58","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1164\/arrd.1978.117.6.991","volume":"117","author":"DE Kopanoff","year":"1978","unstructured":"Kopanoff, D. E., Snider, D. E. Jr. & Caras, G. J. Isoniazid-related hepatitis: A US Public Health Service cooperative surveillance study. Am. Rev. Respir. Dis. 117, 991\u20131001. https:\/\/doi.org\/10.1164\/arrd.1978.117.6.991 (1978).","journal-title":"Am. Rev. Respir. Dis."},{"key":"78737_CR59","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1164\/rccm.201101-0181OC","volume":"184","author":"BP Linas","year":"2011","unstructured":"Linas, B. P., Wong, A. Y., Freedberg, K. A. & Horsburgh, C. R. Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am. J. Respir. Crit. Care Med. 184, 590\u2013601. https:\/\/doi.org\/10.1164\/rccm.201101-0181OC (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78737_CR60","doi-asserted-by":"publisher","first-page":"e14014","DOI":"10.1371\/journal.pone.0014014","volume":"5","author":"R Steffen","year":"2010","unstructured":"Steffen, R. et al. Patients\u2019 costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS ONE 5, e14014. https:\/\/doi.org\/10.1371\/journal.pone.0014014 (2010).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78737-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:56:36Z","timestamp":1670374596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78737-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78737"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78737-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"20 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21823"}}